GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Net Loan

BioXcel Therapeutics (FRA:BX2) Net Loan


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Net Loan?

Net Loan only applies to banks and insurance companies.


BioXcel Therapeutics (FRA:BX2) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.